M2 PRESSWIRE-September 2, 2019-:
Cancer Stem Cells Market to Grow at $1.6 Billion by 2025 | Key Industry Players - Thermo Fisher Scientific, Inc.; AbbVie, Inc.; Merck KGaA; Bionomics; and Lonza
"There is a lot of variability and some of the cells, like
cancer stem cells, are much nastier.
Singapore, Singapore, May 30, 2019 --(PR.com)-- In a landmark study, scientists at the Agency for Science, Technology and Research's (A*STAR) Genome Institute of Singapore (GIS), Bioprocessing Technology Institute (BTI) and oncologists at the National Cancer Centre Singapore (NCCS), have discovered that
cancer stem cells, the founder cells of a tumour, have unique nutrient requirements.
Until now, researchers have assumed that the growth of solid tumors originates from
cancer stem cells characterized by specific surface markers, which develop in a fixed, hierarchical order.
Making up just 0.2 per cent of the total population, the most dynamic
cancer stem cells had special characteristics and significantly higherthan-average energy levels.
When
cancer stem cells, however, switch from metabolizing sugar to metabolizing protein, they become vulnerable to destruction by the drug venetoclax, recently tested in a clinical trial.
Researchers at Boston Children's Hospital reported that this therapy boosts
cancer stem cells that are believed to drive tumors.
The research, published in Oncotarget, is the first evidence that vitamin C (ascorbic acid) can be used to target and kill
cancer stem cells (CSCs), the cells responsible for fueling fatal tumors.
Cancer stem cells (CSCs) are a subpopulation of tumor cells with self-renewal and differentiation potential.
EMP2 is implicated as an oncoprotein in cancer biology and in addition to its overexpression associated with tumor-promoting activities in various tumor types, it has been shown to play a role in signaling migration and invasion of
cancer stem cells.